CT83 Antibody

What is CT83 and why is it significant in cancer research?

CT83 belongs to the Cancer/Testis Antigens (CTAs) family, proteins primarily expressed in testicular tissue but not in other normal tissues, while showing heightened expression in various tumors. The CT83 gene is located on chromosome Xq22 and encodes a 113-amino acid protein .

CT83 has gained significant interest as it exhibits differential expression across multiple cancers including:

• Non-small cell lung cancer (32.6%)

• Triple negative breast cancer (75%)

• Gastric cancer (81.6%)

• Colorectal cancer (62.5%)

• Nasopharyngeal cancer (90.2%)

The restricted expression pattern makes CT83 particularly attractive for targeted therapies with potentially minimal side effects on normal tissues .

What are the key specifications of commonly available CT83 antibodies?

Commercial CT83 antibodies have distinct specifications optimized for different experimental applications:

How should researchers validate the specificity of CT83 antibodies?

Validation of CT83 antibody specificity requires multiple complementary approaches:

• Western blotting: Confirm the antibody detects a single band at ~14 kDa in positive control lysates from cell lines known to express CT83 (RKO, SW1116, NCI-H1299, HuH-7, HeLa, MCF-7, MDA-MB-231, HNE-1, CNE-2)

• Immunohistochemistry: Verify specific staining in CT83-positive cancer tissues with minimal background in normal tissues (except testis)

• Epitope competition: Pre-incubate antibody with the immunizing peptide sequence to confirm signal elimination

• Cross-species reactivity: Note that human CT83 shows limited homology with orthologs (mouse 30%, rat 30%), which may affect cross-reactivity studies

What is the optimal protocol for CT83 immunohistochemistry?

For optimal immunohistochemical detection of CT83 in formalin-fixed paraffin-embedded (FFPE) tissues:

• Sample preparation:

  • Cut 4 μm tissue sections from paraffin blocks

  • Bake, deparaffinize, and rehydrate sections

• Antigen retrieval:

  • Heat-induced epitope retrieval in 10 mmol/L citrate buffer (pH 6.0)

  • Use pressure cooker method for 10 minutes

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Dilute CT83 antibody 1:500-1:1000

  • Incubate overnight at 4°C

• Detection and visualization:

  • Apply HRP-conjugated secondary antibody

  • Develop with diaminobenzidine (DAB)

  • Positive signal appears as brown granules in cytoplasm and cell membranes

How can CT83 antibodies be optimized for western blotting applications?

For successful western blot detection of CT83:

• Sample preparation:

  • Use total protein extraction with complete protease inhibitor cocktail

  • Include positive controls (recombinant CT83 or lysates from CT83-expressing cell lines)

• Electrophoresis and transfer:

  • Use higher percentage gels (15-18%) for optimal resolution of the small (~14 kDa) CT83 protein

  • Transfer to PVDF membrane at lower voltage for longer time to ensure efficient transfer of small proteins

• Antibody concentration:

  • Typical working concentration: 1 μg/ml

  • Optimize through titration if needed

  • Include proper controls and molecular weight markers to confirm specificity

What considerations are important when designing flow cytometry experiments with CT83 antibodies?

When using CT83 antibodies for flow cytometry:

• Cell preparation:

  • Optimize fixation and permeabilization conditions, as CT83 has been detected in both cell membrane and cytoplasm

  • Test different permeabilization reagents (saponin vs. Triton X-100) to maintain epitope integrity

• Controls and validation:

  • Include isotype controls at matching concentrations

  • Use CT83-positive cell lines as positive controls

  • Consider fluorescence-minus-one (FMO) controls for multicolor panels

• Analysis parameters:

  • Analyze both percentage of positive cells and mean fluorescence intensity

  • Consider potential heterogeneity of CT83 expression within tumor cell populations

How can CT83 antibodies be utilized in targeted photodynamic therapy research?

CT83 antibodies show promising potential in targeted photodynamic therapy (PDT) research:

• Antibody-photosensitizer conjugation:

  • CT83 mAb 7G4 can be effectively conjugated with Gallium (III) 5, 10, 15-tris (ethoxycarbonyl) corrole (1-Ga), a photosensitizer for PDT

  • The resulting 7G4-1-Ga complex maintains high specificity for CT83

• Targeted delivery advantages:

  • Conjugates demonstrate greater cytotoxicity to CT83-expressing cancer cells compared to unconjugated photosensitizer

  • Selective targeting reduces potential off-target phototoxicity - a significant limitation of conventional PDT

• Experimental validation methods:

  • ELISA and flow cytometry can confirm preserved binding specificity after conjugation

  • Cytotoxicity assays under light activation determine therapeutic efficacy

  • CT83-negative cell lines serve as essential specificity controls

What role might CT83 antibodies play in developing T-cell receptor-engineered T cell therapies?

CT83 antibodies can contribute significantly to T-cell receptor (TCR) therapy development:

• Target validation:

  • CT83 antibodies help confirm protein expression in tumor samples being considered for TCR-T therapy

  • Immunohistochemistry with CT83 antibodies can identify patient populations most likely to benefit

• Therapy monitoring:

  • CT83 antibodies can track target expression during treatment

  • This monitoring helps identify potential antigen escape mechanisms

• Mechanism studies:

  • CT83 antibodies enable investigation of how natural high-avidity TCRs recognize CT83-expressing tumors

  • They help characterize tumor regression mechanisms in preclinical models of stomach, lung, and breast cancers

How can researchers quantitatively analyze CT83 expression patterns across different cancer types?

For rigorous quantitative analysis of CT83 expression:

• Standardized scoring systems:

  • Implement H-score method (intensity × percentage of positive cells)

  • Alternative: Allred scoring combining proportion and intensity

  • Digital image analysis improves objectivity and reproducibility

• Multi-modal confirmation:

  • Correlate protein detection (IHC/WB with CT83 antibodies) with mRNA expression

  • Compare different CT83 antibody clones to validate expression patterns

• Expression databases integration:

  • Compare findings with The Human Protein Atlas data, which shows CT83 transcripts in lung, stomach, colorectal, urothelial, cervical, and breast cancers

  • Interpret results in context of cancer subtype and clinical parameters

What are common pitfalls in CT83 antibody-based immunohistochemistry and how can they be resolved?

How should researchers interpret discrepancies between CT83 antibody results and mRNA expression data?

When confronting discrepancies between protein and mRNA data:

• Biological explanations:

  • Post-transcriptional regulation may result in different protein vs. mRNA levels

  • Alternative splicing could create protein variants not detected by certain antibodies

  • Protein stability and turnover rates affect steady-state protein levels

• Technical considerations:

  • Confirm antibody specificity using multiple controls

  • Verify primer specificity for mRNA detection

  • Consider sensitivity thresholds of different detection methods

• Resolution approaches:

  • Use multiple antibody clones targeting different CT83 epitopes

  • Implement orthogonal detection methods

  • Perform cell fractionation to investigate protein localization

  • Consider translational regulation mechanisms specific to cancer contexts

What factors influence reproducibility in CT83 antibody-based experimental systems?

Key factors affecting reproducibility include:

• Antibody-related variables:

  • Lot-to-lot variations in commercial antibodies

  • Storage conditions and freeze-thaw cycles

  • Working concentration optimization for each application

• Sample preparation factors:

  • Fixation duration and conditions for IHC samples

  • Protein extraction methods for western blotting

  • Cell preparation protocols for flow cytometry

• Standardization approaches:

  • Include consistent positive and negative controls across experiments

  • Document detailed protocols including antibody dilutions, incubation times, and temperatures

  • Validate findings with multiple experimental approaches

How might CT83 antibodies contribute to developing companion diagnostics for cancer immunotherapies?

CT83 antibodies have significant potential in companion diagnostics development:

• Patient stratification:

  • CT83 IHC could identify patients likely to respond to CT83-targeted therapies

  • Quantitative assessment might establish expression thresholds for treatment eligibility

• Monitoring applications:

  • Serial biopsies with CT83 antibody staining could track antigen expression during treatment

  • Potential development of circulating tumor cell detection using CT83 antibodies

• Multiparameter diagnostics:

  • CT83 antibodies could be incorporated into multiplexed IHC panels

  • Co-expression analysis with other immune markers could predict immunotherapy response

What technological advancements might improve CT83 antibody specificity and sensitivity?

Emerging technologies to enhance CT83 antibody performance include:

• Antibody engineering approaches:

  • Development of recombinant antibody fragments with improved tissue penetration

  • Humanization or fully human antibodies to reduce immunogenicity in therapeutic applications

  • Affinity maturation to enhance detection of low CT83 expression

• Detection system innovations:

  • Signal amplification technologies for detecting low abundance CT83

  • Multiplexed detection systems for co-expression analysis

  • Proximity ligation assays to study CT83 protein interactions

• Novel formats:

  • Bispecific antibodies targeting CT83 and immune effector cells

  • Site-specific conjugation technologies for improved antibody-drug conjugates

  • pH-responsive antibodies for enhanced internalization in therapeutic applications

How can CT83 antibody-based research contribute to understanding the functional role of CT83 in cancer biology?

CT83 antibodies can advance fundamental understanding of CT83 biology through:

• Protein interaction studies:

  • Immunoprecipitation to identify CT83 binding partners

  • Proximity labeling approaches to map CT83 protein interactome

  • Co-localization studies to determine subcellular distribution

• Functional investigations:

  • Blocking antibodies to investigate CT83's role in cancer cell processes

  • Internalizing antibodies for targeted disruption of CT83 function

  • Correlating CT83 expression patterns with phenotypic characteristics

• Structure-function analysis:

  • Epitope mapping to identify functionally important domains

  • Conformation-specific antibodies to detect active vs. inactive states

  • Combining structural biology approaches with antibody-based detection

What are best practices for incorporating CT83 antibodies in translational cancer research?

For optimal integration of CT83 antibodies in translational research:

• Validation rigor:

  • Always validate antibody specificity in your experimental system

  • Include multiple controls appropriate for each application

  • Consider orthogonal validation with independent antibody clones

• Context consideration:

  • Interpret CT83 expression in context of tumor type and molecular subtype

  • Consider tumor microenvironment and immune contexture

  • Correlate findings with clinical parameters when possible

• Collaborative approach:

  • Combine expertise from immunology, oncology, and antibody technology

  • Share detailed methodological information in publications

  • Contribute to standardization efforts in the field